How to Audit Your Audit Risks and Legal Exposure Management Process Before Inspectors Do

In the highly regulated pharmaceutical industry, managing audit risks and legal exposure is imperative, especially for companies dealing with controlled substances. Compliance with regulatory guidelines is not merely a box-checking exercise; it is a critical component of maintaining operational integrity and ensuring patient safety. This regulatory explainer manual aims to provide comprehensive insights into the auditing process of audit risks and legal exposure management of controlled substances, focusing on relevant regulations, documentation requirements, and agency expectations in the US, UK, and EU markets.

Context

The management of audit risks and legal exposure is a vital component of a pharmaceutical company’s compliance strategy, especially when it pertains to controlled substances. The legal framework governing these substances is defined through an array of laws and regulatory guidelines that dictate how companies must handle manufacturing, distribution, and record keeping related to these highly regulated products.

Organizations must be well-versed in various regulatory requirements established by the FDA, EMA, and MHRA. The adherence to these regulations not only safeguards the organization from potential legal ramifications but also reinforces the overall trust in pharmaceutical products and practices.

Legal/Regulatory Basis

The legal basis for the management of controlled substances is chiefly anchored in the following regulations:

• 21 CFR Parts 1300–1399 (Controlled Substances Act – USA): This part contains the legal framework for the registration, control, and handling of controlled substances, including Schedule I to Schedule V substances based on their medical utility and potential for abuse.
• EU Directive 2001/83/EC: Governing medicinal products in the EU, this directive outlines the necessary compliance parameters for obtaining marketing authorizations and managing the sale and distribution of controlled substances.
• UK Misuse of Drugs Act 1971: Provides the primary legal framework in the UK for managing controlled substances. Compliance with this act is paramount for organizations engaged in the production or distribution of these substances.
• ICH Guidelines (International Conference on Harmonisation): Guidelines set forth to harmonize regulatory requirements across various regions, particularly concerning Clinical Trials and Good Manufacturing Practices.

Documentation

Maintaining comprehensive documentation is essential in audit risk management, as it serves both as a compliance measure and a defense during audits. Companies should ensure that the following documentation practices are executed thoroughly:

Essential Documentation Practices

• Auditing Procedures: Document standard operating procedures (SOPs) for conducting internal audits specific to controlled substances compliance. This should include specifics regarding sampling, documentation control, and reporting findings.
• Compliance Checklists: Utilize compliance checklists tailored for controlled substances to ensure that all regulatory aspects are systematically addressed.
• Audit Trails: Create and maintain robust audit trails that track all changes made to documentation, storage conditions, and equipment used in the processing of controlled substances.
• Training Records: Document all training conducted for personnel involved in handling controlled substances to ensure compliance with current regulatory requirements.

Review/Approval Flow

Understanding the review and approval flow for managing audit risks and legal exposure is crucial for strategic planning. Here are the primary steps involved:

Phase 1: Internal Review

Before any documentation is submitted to regulatory authorities, internal reviews should be conducted. This often involves the following:

• Cross-departmental review involving Regulatory Affairs, Quality Assurance, and Legal teams.
• Preparation of a detailed risk assessment that profiles potential legal exposures.
• Submission of internal audit findings to senior management for strategic oversight.

Phase 2: Submission to Regulatory Authorities

Once internal reviews are complete, the documentation and summary findings must be submitted to relevant authorities. Key considerations include:

• Choosing the appropriate submission pathway (e.g., new application vs. variation).
• Justifying any bridging data required for approvals based on specific changes to controlled substances.
• Ensuring the inclusion of complete application forms and all required supporting documents.

Phase 3: Post-Submission Monitoring

After submission, it is critical to monitor the application status and address any follow-up queries by regulatory authorities promptly. This flow typically entails:

• Establishing a timeline for addressing agency queries.
• Reviewing agency communication for clarity on any concerns raised.
• Developing a response plan that includes reiterating compliance measures in place.

Common Deficiencies

Understanding common deficiencies that may arise during audits can help companies establish preventive measures. Below are identified shortcomings:

Lack of Comprehensive Documentation

Many companies fail to maintain adequate records of their handling of controlled substances. This can include missing audit trails, inadequate SOPs, and insufficient training documentation.

Failure to Address Regulatory Updates

Regulatory landscapes are dynamic; failure to stay up-to-date with changing compliance requirements can lead to significant compliance gaps. Regular training and review of legal changes must be integrated into company procedures.

Inadequate Risk Assessments

Many organizations do not conduct thorough risk assessments, which can hinder the ability to develop effective audit strategies. A reliable assessment must include an evaluation of existing controls and the identification of possible vulnerabilities.

Regulatory Affairs-Specific Decision Points

As part of the audit process, there are crucial decision points where Regulatory Affairs (RA) must navigate complexities pertaining to compliance. These include:

Variation vs. New Application

RA teams must be adept at determining whether an intended change to a controlled substance qualifies as a variation or necessitates a new application. The factors influencing this decision include:

• The scope of the change (e.g., formulation, manufacturing process).
• Impact on safety and efficacy data.
• Time sensitivity of the changes relative to market demands.

Bridging Data Justification

In circumstances where historical data is to be bridged with new data, it is critical for RA teams to provide robust justification for this approach. Factors to consider include:

• Relevance of the historical data to current regulations.
• Consistency in methodology between datasets.
• Precedent examples from agency approvals that may favor a bridging approach.

Practical Tips for Documentation and Responses

To ensure a robust audit risk and legal exposure management process, consider the following practical tips:

Documentation Recommendations

• Employ a centralized document management system that simplifies retrieval and archival processes.
• Utilize templates for recurring documentation (e.g., audit reports, risk assessments) to ensure consistency and compliance.
• Schedule regular internal audits to assess compliance and identify areas of improvement.

Response Strategies for Agency Queries

• Respond to agency inquiries within stipulated timelines to demonstrate commitment to compliance.
• Be clear and concise in responses; avoid jargon and ensure that the focus remains on regulatory clarity.
• In cases of deficiencies, provide evidence of corrective action taken and future prevention strategies.

Conclusion

Conducting thorough audits of audit risks and legal exposure management processes for controlled substances is vital for compliance and operational integrity. By understanding the legal frameworks, establishing meticulous documentation practices, and leveraging strategic decision-making, pharmaceutical companies can enhance their readiness for inspections and regulatory scrutiny. The proactive stance in managing audit risks not only minimizes legal exposure but also fosters an environment of trust and transparency in pharmaceutical practices. As regulatory landscapes evolve, staying informed and adaptable will be key to successful compliance management.